dazodalibep

News

Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.

News

Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.